Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J)

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Juntendo University; Juntendo University Hospital
• Collaborator: Japan Heart Foundation
• Treatments: Amlodipine; Calcium; Calcium Channel Blockers

Criteria

Inclusion Criteria:

• Age: Between 20 and 79 years (at the time of giving informed consent).

• Sex: Either sex.

• Admission status: Outpatients.

• Patients requiring treatment for hypertension according to the JSH 2004 hypertension therapy guidelines before beginning this study

• Patients who have not used any calcium antagonists for at least 4 weeks before the beginning of this study.

• Patients who are scheduled to undergo elective PCI.

Exclusion Criteria:

• Patients with acute coronary syndrome (ACS).

• Patients who have experienced Q-wave myocardial infarction within 4 weeks before beginning this study.

• Patients with renal dysfunction (serum creatinine >2.0 mg/dL).

• Patients in whom PCI is unsuccessful.

• Patients with cardiogenic shock.

• Patients with moderate or severe congestive heart failure.

• Patients with 50% or more stenosis of the main trunk of the left coronary artery.

• Patients with other problems whom the investigator considers unsuitable for this study.